Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
TheraPharm GmbH maintains a presence in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This action is being processed by 1 distinct examiner, indicating that the company's current interactions with the patent office are highly centralized. The data shows that the portfolio is currently interacting with only 1 distinct art unit, which reflects a narrow technical focus for the pending applications. This structure implies that the applications are being evaluated within a single specialized division.
The busiest examiner for the portfolio is SCHLIENTZ, LEAH H, who is currently handling the 1 pending office action. This single examiner's pending count of 1 matches the total number of pending actions for the company, meaning no other examiners are currently active. For practitioners, this highlights the importance of understanding the specific preferences and history of this examiner. The prosecution environment is streamlined, with all active matters consolidated under one individual in one specific art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17892739 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | SCHLIENTZ, LEAH H | 71d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17892739 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | SCHLIENTZ, LEAH H | 1618 | §103 | Final Rejection | 71d overdue | Pending | Aug 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial